GLP-1 Receptor Agonist Randomized Trial Evidence
This article reviews GLP-1 receptor agonist randomized trial data focusing on weight loss and metabolic improvements. Semaglutide and tirzepatide clinical trials provide key insights into efficacy and safety. Understanding this data helps clinicians…
Losing Weight on GLP-1s? Do Not Lose Your Muscle
Clinical Takeaway GLP-1 medications can cause loss of lean muscle alongside fat, so pairing them with adequate protein intake and resistance exercise is essential to protect your strength and metabolism. Talk to your doctor about strategies to preserve…
Your Body Fights Back, But Your Doctor Has Options
Clinical Takeaway GLP-1 plateaus happen because the body adapts by slowing metabolism and increasing hunger signals over time. Clinicians may adjust dosing, add adjunct therapies, or address behavioral factors to push past the stall. Your Body Fights…
Semaglutide Weight Management Medicine: Surgery Safety Guide
Perioperative management semaglutide is critical for surgery safety due to delayed gastric emptying risks. GLP-1 receptor agonists like semaglutide increase aspiration risk during anesthesia. Proper coordination between prescribers and surgical teams is…
Same Drug, Different Goals: GLP-1s Treat More Than Sugar
Clinical Takeaway GLP-1 medications like semaglutide are FDA-approved for both type 2 diabetes management and chronic weight loss, but the target doses, titration schedules, and treatment goals can differ significantly between the two indications. Talk…
Comparing Semaglutide and Tirzepatide: Cardiovascular Outcomes
This article reviews semaglutide tirzepatide cardiovascular outcomes evidence to inform clinical decisions. Both drugs offer benefits for obesity and cardiometabolic risk. Understanding their cardiovascular profiles is essential for personalized GLP-1…
GLP-1 Receptor Agonist Restart: What the Evidence Shows
Discontinuation and restart of GLP-1 receptor agonist therapy are clinically significant due to documented weight regain after stopping treatment. Patients often restart these medications, including semaglutide and tirzepatide, despite challenges.…
FDA Safety Review of Eli Lilly’s Oral GLP-1 Weight Loss Pill
The oral GLP-1 weight loss pill by Eli Lilly is under FDA safety review to assess its unique pharmacokinetics and risk profile. This review highlights the differences between oral and injectable GLP-1 therapies. Clinicians should stay informed on…
Avoiding the Biggest Clinical Mistakes in GLP-1 Receptor Agonist Use
GLP-1 receptor agonist clinical mistakes often reduce treatment effectiveness and safety. Patients frequently discontinue therapy prematurely or mismanage dosing. Recognizing and addressing these errors is essential for optimal weight management outcomes.
Semaglutide Weight Management: Ozempic Face & Skin Effects
Semaglutide facial volume loss is a key concern during rapid weight management with Ozempic. This phenomenon, often called 'Ozempic face,' results from fat loss rather than direct drug effects. Understanding these skin changes helps patients and…